Haematopoietic stem cell transplantation: Current status

National Medical Journal of India

Volumn 20, Issue 3, 2007, Pages 128-137

  Kumar, Lalit ^a  

^a INSTITUTE ROTARY CANCER HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AMIFOSTINE; BUSULFAN; CARBOPLATIN; CARMUSTINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DEFIBROTIDE; DIURETIC AGENT; ETOPOSIDE; FLUDARABINE; IDARUBICIN; IFOSFAMIDE; INTERFERON; MELPHALAN; MESNA; METHOTREXATE; MONOCLONAL ANTIBODY; OPIATE; PALIFERMIN; PENTAMIDINE; PLACEBO; PREDNISOLONE; RECOMBINANT INTERLEUKIN 2; RITUXIMAB; THYMOCYTE ANTIBODY; UNINDEXED DRUG;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ALLOGENIC BONE MARROW TRANSPLANTATION; APLASTIC ANEMIA; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER RELAPSE; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; DONOR SELECTION; DRUG ABSORPTION; DRUG MEGADOSE; ENGRAFTMENT SYNDROME; FANCONI ANEMIA; FIBRINOLYSIS; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMORRHAGIC CYSTITIS; HIGH RISK PATIENT; HLA TYPING; HODGKIN DISEASE; HUMAN; IMMUNE DEFICIENCY; INBORN ERROR OF METABOLISM; INDIA; INTERSTITIAL PNEUMONIA; LUNG FIBROSIS; LUNG HEMORRHAGE; MORBIDITY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; NONHUMAN; NONMYELOABLATIVE CONDITIONING; PNEUMOCYSTIS PNEUMONIA; REDUCED INTENSITY CONDITIONING; REVIEW; RISK REDUCTION; SICKLE CELL ANEMIA; SOLID TUMOR; STEM CELL MOBILIZATION; STOMATITIS; THALASSEMIA MAJOR; TREATMENT INDICATION; TREATMENT RESPONSE; UMBILICAL CORD; VEIN OCCLUSION; WHOLE BODY RADIATION;

ANEMIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, NON-HODGKIN; METABOLIC DISEASES; MULTIPLE MYELOMA; NEOPLASMS; TISSUE DONORS; TRANSPLANTATION;

EID: 34548212304     PISSN: 0970258X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Armitage JO. Bone marrow transplantation. N Engl J Med 1994; 330:827-38.
2. Bedi R, Kumar L, Kochupillai V. Autologous peripheral blood stem cell transplantation: Predictors for haematopoietic reconstitution. Natl Med J India 2003;16:255-9.
3. Bone Marrow Donors Worldwide. Available at www.bmdw.org (accessed on 10 February 2007).
4. Petersdorf EW, Smith AG. High resolution donor HLA-matching: Saving lives. CIBMTR (Centre for International Blood and Marrow Transplant Research) Newletter 2006;12:1-4.
5. Dey BR, Spitzer TR. Current status of haploidentical stem cell transplantation. Br J Haematol 2006;135:423-37.
6. Stem Cell Trialists' Collaborative Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: An individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005;23:5074-87.
7. Pasquini M. CIBMTR summary slides 2005. CIBMTR (Centre for International Blood and Marrow Transplant Research) Newletter 2006; 12:5-8.
8. Tse W, Laughlin MJ. Umbilical cord blood transplantation: A new alternative option. Hematology Am Soc Hematol Educ Program 2005;377-83.
9. Ballen KK, Spitzer TR, Yeap BY, McAfee S, Dey BR, Attar E, et al. Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant 2007;13:82-9.
10. Raju GM, Kochupillai V, Kumar L. Storage of haemopoietic stem cells for autologous bone marrow transplantation. Natl Med J India 1995; 8:216-21.
11. Gulati SC, Duensing S. Evaluating the benefit of purging in stem cell transplantation. Cancer Invest 1994;12:447-9.
12. Forman SJ. Hematopoietic cell transplantation. In: Pazdur R, Coia LR, Hoskins WJ, Wagman LD (eds). Cancer management: A multidisciplinary approach. New York:The Oncology Group; 2003:801-17.
13. Socié G, Clift RA, Blaise D, Devergie A, Ringden O, Martin PJ, et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: Long-term follow-up of 4 randomized studies. Blood 2001;98:3569-74.
14. Madden T, de Lima M, Thapar N, Nguyen J, Roberson S, Couriel D, et al. Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: A comparison with an every 6-hour dosing schedule. Biol Blood Marrow Transplant 2007; 13:56-64.
15. 2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: Final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial. Blood 2002;99:731-5.
16. Giralt S. Reduced-intensity conditioning regimens for hematologic malignancies: What have we learned over the past 10 years? In: Berliner N, Lee SJ, Linenberger M, Vogelsang GB (eds). Hematology 2005. Washington DC:American Society of Hematology Education Program; 2005:96-103.
17. Peggs KS. Cytomegalovirus following stemcell transplantation: From pharmacologic to immunologic therapy. Expert Rev Anti Infect Ther 2004;2:559-73.
18. Yuen KY, Woo PC. Tuberculosis in blood and marrow transplant recipients. Hematol Oncol 2002;20:51-62.
19. Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2005;352:1264-5.
20. Spencer A, Horvath N, Gibson J, Prince HM, Herrmann R, Bashford J, et al; Australasian Leukemia and Lymphoma Group. Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplant 2005;35:971-7.
21. Afessa B, Tefferi A, Litzow MR, Peters SG. Outcome of diffuse alveolar hemorrhage in hematopoietic stem cell transplant recipients. Am J Respir Crit Care Med 2002;166:1364-8.
22. Cahill RA, Spitzer TR, Mazumder A. Marrow engraftment and clinical manifestations of capillary leak syndrome. Bone Marrow Transplant 1996;18:177-84.
23. Mossad S, Kalaycio M, Sobecks R, Pohlman B, Andresen S, Avery R, et al. Steroids prevent engraftment syndrome after autologous hematopoietic stem cell transplantation without increasing the risk of infection. Bone Marrow Transplant 2005;35:375-81.
24. Marsh JC, Ball SE, Darbyshire P, Gordon-Smith EC, Keidan AJ, Martin A, et al. Guidelines for the diagnosis and management of acquired aplastic anaemia. Br J Haematol 2003;123:782-801.
25. Leung AY, Mak R, Lie AK, Yuen KY, Cheng VC, Liang R, et al. Clinicopathological features and risk factors of clinically overt haemorrhagic cystitis complicating bone marrow transplantation. Bone Marrow Transplant 2002;29:509-13.
26. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Ann Intern Med 1993;118:255-67.
27. Richardson PG, Murakami C, Jin Z, Warren D, Momtaz P, Hoppensteadt D, et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: Response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 2002;100:4337-43.
28. Corbacioglu S, Greil J, Peters C, Wulffraat N, Laws HJ, Dilloo D, et al. Defibrotide in the treatment of children with veno-occlusive disease (VOD): A retrospective multicentre study demonstrates therapeutic efficacy upon early intervention. Bone Marrow Transplant 2004;33:189-95.
29. Deeg HJ, Antin JH. The clinical spectrum of acute graft-versus-host disease. Semin Hematol 2006;43:24-31.
30. Socie G. Graft-versus-host disease - from the bench to the bedside? N Engl J Med 2005;353:1396-7.
31. Lowsky R, Takahashi T, Liu YP, Dejbakhsh-Jones S, Grumet FC, Shizuru JA, et al. Protective conditioning for acute graft-versus-host disease. N Engl J Med 2005;353:1321-31.
32. Higman MA, Vogelsang GB. Chronic graft versus host disease. Br J Haematol 2004;125:435-54.
33. Kumar L. Leukemia: Management of relapse after allogeneic bone marrow transplantation. J Clin Oncol 1994;12:1710-17.
34. Deeg HJ, Leisenring W, Storb R, Nims J, Flowers ME, Witherspoon RP, et al. Long-term outcome after marrow transplantation for severe aplastic anemia. Blood 1998;91:3637-45.
35. Alter BP. Bone marrow failure: A child is not just a small adult (but an adult can have a childhood disease). In: Berliner N, Lee SJ, Linenberger M, Vogelsang GB (eds). Hematology 2005. Washington, DC:American Society of Hematology Education Program; 2005:96-103.
36. Lucarelli G, Galimberti M, Giardini C, Polchi P, Angelucci E, Baronciani D, et al. Bone marrow transplantation in thalassemia: The experience of Pesaro. Ann N Y Acad Sci 1998;850:270-5.
37. Chandy M, Srivastava A, Dennison D, Mathews V, George B. Allogeneic bone marrow transplantation in the developing world: Experience from a center in India. Bone Marrow Transplant 2001;27:785-90.
38. Ramzi M, Nourani H, Zakernia M, Hamidian Jahromi AR. Hematopoietic stem cell transplantation for beta-thalassemia major: Experience in south of Iran. Transplant Proc 2004;36:2509-10.
39. Walter Mark C. Stem cell therapy for sickle cell disease: Transplantation and gene therapy. In: Berliner N, Lee SJ, Linenberger M, Vogelsang GB (eds). Hematology 2005. Washington DC:American Society of Hematology Education Program; 2005:66-73.
40. Fischer A, Landais P, Friedrich W, Morgan G, Gerritsen B, Fasth A, et al. European experience of bone-marrow transplantation for severe combined immunodeficiency. Lancet 1990;336:850-4.
41. Fischer A, Landais P, Friedrich W, Gerritsen B, Fasth A, Porta F, et al. Bone marrow transplantation (BMT) in Europe for primary immunodeficiencies other than severe combined immunodeficiency: A report from the European Group for BMT and the European Group for Immunodeficiency. Blood 1994;83:1149-54.
42. Muenzer J, Fisher A. Advances in the treatment of mucopolysaccharidosis type I. N Engl J Med 2004;350:1932-4.
43. Peters C, Steward CG; National Marrow Donor Program; International Bone Marrow Transplant Registry; Working Party on Inborn Errors, European Bone Marrow Transplant Group. Hematopoietic cell transplantation for inherited metabolic diseases: An overview of outcomes and practice guidelines. Bone Marrow Transplant 2003;31:229-39.
44. O'Donnell MR. The role of autologous and allogeneic (full and mini) stem cell transplantation in AML. In: Broudy VC, Berliner N, Larson RA, Leung. LL (eds). Hematology 2004. Washington, DC:American Society of Hematology Educational. Program Book; 2004:104-9.
45. Ottmann OG, Wassman B. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. In: Broudy VC, Berliner N, Larson RA, Leung. LL (eds). Hematology 2004. Washington, DC:American Society of Hematology Educational. Program Book; 2004:118-22.
46. Lee S, Kim YJ, Min CK, Kim HJ, Eom KS, Kim DW, et al. The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2005; 105:3449-57.
47. de Witte T, Suciu S, Verhoef G, Labar B, Archimbaud E, Aul C, et al. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood 2001; 98:2326-31.
48. Goldman JM, Melo JV. Chronic myeloid leukemia - advances in biology and new approaches to treatment. N Engl J Med 2003;349:1451-64.
49. Saikia TK, Parikh PM, Tawde S, Amare-Kadam PS, Rajadhyaksha S, Chhaya S. Allogeneic blood stem cell transplantation in chronic myeloid leukaemia-chronic phase following conditioning with busulphan and cyclophosphamide: A follow up report. Natl Med J India 2004; 17:71-3.
50. Crawley C, Szydlo R, Lalancette M, Bacigalupo A, Lange A, Brune M, et al. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: An analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 2005;106:2969-76.
51. Gribben JG, Zahrieh D, Stephans K, Bartlett-Pandite L, Alyea EP, Fisher DC, et al. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood 2005; 106:4389-96.
52. Sorror ML, Maris MB, Sandmaier BM, Storer BE, Stuart MJ, Hegenbart U, et al. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol 2005;23:3819-29.
53. Federico M, Bellei M, Brice P, Brugiatelli M, Nagler A, Gisselbrecht C, et al. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. J Clin Oncol 2003; 21:2320-5.
54. Peggs KS, Hunter A, Chopra R, Parker A, Mahendra P, Milligan D, et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 2005; 365:1934-41.
55. Milpied N, Deconinck E, Gaillard F, Delwail V. Foussard C, Berthou C, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004;350:1287-95.
56. Besien KV. Autologous and allogeneic stem cell transplantation in follicular lymphoma. In: Broudy VC, Berliner N, Larson RA, Leung LL (eds). Hematology 2004. Washington, DC: American Society of Hematology Educational Program Book; 2004:244-8.
57. Schouten HC, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnson HE, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: Results from the randomized European CUP trial. J Clin Oncol 2003; 21:3918-27.
58. Lemieux B, Tartas S, Traulle C, Espinouse D, Thieblemont C, Bouafia F, et al. Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 2004;33: 921-3.
59. Kumar L, Vikram P, Kochupillai V. Recent advances in the management of multiple myeloma. Natl Med J India 2006;19:80-9.
60. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais do Myelome. N Engl J Med 1996;335:91-7.
61. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003;349:2495-502.
62. Kumar L, Raju GM, Ganessan K, Shawgi S, Menon H, Wadhwa J, et al. High dose chemotherapy followed by autologous haemopoietic stem cell transplantin multiple myeloma. Natl Med J India 2003; 16:16-21.
63. Maloney DG, Molina AJ, Sahebi F, Stockerl-Goldstein KE, Sandmaier BM, Bensinger W, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003;102:3447-54.
64. Harousseau JL, Attal M, Facon Th, Avet-Loiseau H, Moreau P. Stem cell transplantation in multiple myeloma. In: Broudy VC, Berliner N, Larson RA, Leung LL (eds). Hematology 2004. Washington, DC:American Society of Hematology Educational Program Book; 2004:244-8.
65. Tallman MS, Gray R, Robert NJ, LeMaistre CF, Osborne CK, Vaughan WP, et al. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med 2003;349:17-26.
66. Schmid P, Schippinger W, Nitsch T, Huebner G, Heilmann V, Schultze W, et al. Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: Results of a randomized trial. J Clin Oncol 2005; 23:432-40.
67. Stiff PJ, Veum-Stone J, Lazarus HM, Ayash L, Edwards JR, Keating A, et al. High-dose chemotherapy and autologous stem-cell transplantation for ovarian cancer: An autologous blood and marrow transplant registry report. Ann Intern Med 2000;133:504-15.
68. Vaena DA, Abonour R, Einhom LH. Long-term survival after high-dose salvage chemotherapy for germ cell malignancies with adverse prognostic variables. J Clin Oncol 2003;21:4100-4.
69. Schmoll HJ, Kollmannsberger C, Metzner B, Hartmann JT, Schleucher N, Schoffski P, et al. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: An extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol 2003;21:4083-91.
70. Lotz JP, Bui B, Gomez F, Theodore C, Cary A, Fizazi K, et al. Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation: Results of the phase II multicentric TAXIF trial. Ann Oncol 2005;16:411-18.
71. Dallorso S, Manzitti C, Morreale G, Faraci M, High dose therapy and autologous hematopoietic stem cell transplantation in poor risk solid tumors of childhood. Haematologica 2000;85:66-70.
72. Atra A, Pinkerton R. High-dose chemotherapy in soft tissue sarcoma in children. Crit Rev Oncol Hematol 2002;41:191-6.
73. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999;341:1165-73.
74. Kohler JA, Imeson J, Ellershaw C, Lie SO. A randomized trial of 13-cis retinoic acid in children with advanced neuroblastoma after high-dose therapy. Br J Cancer 2000;83:1124-7.